|
MechanismGnRHR antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date14 Jun 2022 |
A Randomized, Double-blind, Open for Active Comparator, Parallel, Multi-center Phase II Study to Explore the Efficacy, Safety and Tolerability of BG2109 Compared With Cetrorelix During COH in Female Subjects Undergoing ART Procedures
To explore the optimal effective daily dose of BG2109 to suppress premature luteinizing hormone (LH) surge during COH in female subjects undergoing ART procedures.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis
The objective of this study is to demonstrate the efficacy and safety of BG2109 administered orally once daily at a dose of 100 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus placebo, while under randomized treatment, in the management of moderate to severe endometriosis-associated pain (EAP) in chinese women with surgically confirmed endometriosis
一项在中国子宫内膜异位症受试者中评估BG2109的有效性和安全性的多中心、随机、双盲、安慰剂对照III期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of BG2109 in Chinese subjects with endometriosis
评价BG2109治疗子宫内膜异位症中度至重度疼痛患者的有效性及安全性
[Translation] To evaluate the efficacy and safety of BG2109 in the treatment of patients with moderate to severe pain due to endometriosis
100 Clinical Results associated with Shanghai Baozheng Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Shanghai Baozheng Pharmaceutical Technology Co., Ltd.
100 Deals associated with Shanghai Baozheng Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Shanghai Baozheng Pharmaceutical Technology Co., Ltd.